Kymera Therapeutics Financial Statements
NASDAQ: KYMRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kymera Therapeutics revenue and earnings
In fiscal 2025, Kymera Therapeutics generated $39.2 million in revenue, down 16.7% from fiscal 2024, its first annual decline since 2024. Kymera Therapeutics reported a net loss of $311.4 million, compared with a loss of $223.9 million a year earlier. Gross margin was 0.0% (flat year over year) and operating margin -891.1%.
Diluted earnings per share came in at -$3.69. Over the last 5 fiscal years, KYMR's revenue has grown at a 2.9% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Kymera Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Revenue | 39.21M | 47.07M | 78.59M | 46.83M | 72.83M | 34.03M | 2.93M |
| Revenue growth (YoY) | -16.70% | -40.11% | +67.84% | -35.71% | +114.00% | +1059.99% | — |
| Cost of Revenue | 39.21M | 47.07M | 78.59M | 46.83M | — | — | — |
| Gross Profit | 0 | 0 | 0 | 0 | — | — | — |
| Operating Expenses | 388.61M | 308.71M | 244.12M | 208.08M | 173.36M | 80.34M | 45.14M |
| Research & Development | 316.57M | 240.25M | 189.08M | 164.25M | 137.02M | 62.10M | 37.16M |
| Operating Income | -349.40M | -261.63M | -165.53M | -161.26M | -100.53M | -46.30M | -42.20M |
| Other Income (Expense) | 38.05M | 37.78M | 18.57M | 6.45M | 313.00K | 711.00K | 959.00K |
| Pretax Income | -311.35M | — | — | — | — | — | — |
| Income Tax | 0 | — | — | 0 | 0 | 0 | 0 |
| Net Income | -311.35M | -223.86M | -146.96M | -154.81M | -100.22M | -45.59M | -41.25M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| EPS (Basic) | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 | -3.15 | -24.28 |
| EPS (Diluted) | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 | -3.15 | -24.28 |
| Shares Outstanding (Basic) | 84.49M | 75.04M | 58.37M | 53.93M | 47.99M | 17.35M | 1.70M |
| Shares Outstanding (Diluted) | 84.49M | 75.04M | 58.37M | 53.93M | 47.99M | 17.35M | 1.70M |
| EBITDA | -341.09M | -254.26M | -161.97M | -158.28M | -98.13M | -44.54M | -41.38M |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
| Operating Margin | -891.07% | -555.82% | -210.62% | -344.37% | -138.03% | -136.05% | -1438.48% |
| Net Margin | -794.04% | -475.57% | -186.99% | -330.60% | -137.60% | -133.96% | -1405.79% |
This table shows 7 annual periods of Kymera Therapeutics's income statement, from FY 2025 back to FY 2019, across 18 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow KYMR's reporting calendar. What is a income statement?